Is NGNE or CNTB more profitable?

Neurogene's return on equity of -37.88% beat Connect Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Neurogene N/A -37.88% -34.70% Connect Biopharma N/A -122.29% -97.07%

Does the media refer more to NGNE or CNTB?

In the previous week, Connect Biopharma had 1 more articles in the media than Neurogene. MarketBeat recorded 4 mentions for Connect Biopharma and 3 mentions for Neurogene. Connect Biopharma's average media sentiment score of 0.89 beat Neurogene's score of 0.63 indicating that Connect Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neurogene 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Connect Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Is ARVN or CNTB more profitable?

Connect Biopharma has a net margin of 0.00% compared to Arvinas' net margin of -247.54%. Arvinas' return on equity of -44.38% beat Connect Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Arvinas -247.54% -44.38% -28.38% Connect Biopharma N/A -122.29% -97.07%

Does the media favor ARVN or CNTB?

In the previous week, Arvinas and Arvinas both had 4 articles in the media. Connect Biopharma's average media sentiment score of 0.89 beat Arvinas' score of 0.70 indicating that Connect Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arvinas 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Connect Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer STRO or CNTB?

In the previous week, Connect Biopharma had 2 more articles in the media than Sutro Biopharma. MarketBeat recorded 4 mentions for Connect Biopharma and 2 mentions for Sutro Biopharma. Sutro Biopharma's average media sentiment score of 0.93 beat Connect Biopharma's score of 0.89 indicating that Sutro Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sutro Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Connect Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Is CNTB or KYTX more profitable?

Kyverna Therapeutics' return on equity of -81.88% beat Connect Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Connect Biopharma N/A -122.29% -97.07% Kyverna Therapeutics N/A -81.88% -64.87%

Does the media refer more to CNTB or KYTX?

In the previous week, Connect Biopharma had 1 more articles in the media than Kyverna Therapeutics. MarketBeat recorded 4 mentions for Connect Biopharma and 3 mentions for Kyverna Therapeutics. Connect Biopharma's average media sentiment score of 0.89 beat Kyverna Therapeutics' score of 0.63 indicating that Connect Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Connect Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Kyverna Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Connect Biopharma (CNTB) Competitors

$2.20 +0.14 (+6.52%)

Closing price 06/26/2026 03:59 PM Eastern

Extended Trading

$2.25 +0.05 (+2.18%)

As of 06/26/2026 07:55 PM Eastern

Compare

CNTB vs. CTMX, NGNE, ARVN, STRO, and KYTX

Should you buy Connect Biopharma stock or one of its competitors? MarketBeat compares Connect Biopharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Connect Biopharma include CytomX Therapeutics (CTMX), Neurogene (NGNE), Arvinas (ARVN), Sutro Biopharma (STRO), and Kyverna Therapeutics (KYTX). These companies are all part of the "pharmaceutical products" industry.

How does Connect Biopharma compare to CytomX Therapeutics?

CytomX Therapeutics (NASDAQ:CTMX) and Connect Biopharma (NASDAQ:CNTB) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings.

67.8% of CytomX Therapeutics shares are owned by institutional investors. Comparatively, 58.7% of Connect Biopharma shares are owned by institutional investors. 3.8% of CytomX Therapeutics shares are owned by insiders. Comparatively, 22.6% of Connect Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

CytomX Therapeutics has higher revenue and earnings than Connect Biopharma. CytomX Therapeutics is trading at a lower price-to-earnings ratio than Connect Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CytomX Therapeutics	$76.20M	7.56	-$17.37M	-$0.41	N/A
Connect Biopharma	$60K	2,313.78	-$55.48M	-$1.15	N/A

CytomX Therapeutics presently has a consensus target price of $12.10, indicating a potential upside of 257.46%. Connect Biopharma has a consensus target price of $7.17, indicating a potential upside of 225.02%. Given CytomX Therapeutics' higher probable upside, analysts clearly believe CytomX Therapeutics is more favorable than Connect Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CytomX Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91
Connect Biopharma	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Connect Biopharma had 3 more articles in the media than CytomX Therapeutics. MarketBeat recorded 4 mentions for Connect Biopharma and 1 mentions for CytomX Therapeutics. CytomX Therapeutics' average media sentiment score of 1.89 beat Connect Biopharma's score of 0.89 indicating that CytomX Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
CytomX Therapeutics	Very Positive
Connect Biopharma	Positive

CytomX Therapeutics has a beta of 2.08, meaning that its share price is 108% more volatile than the broader market. Comparatively, Connect Biopharma has a beta of -0.22, meaning that its share price is 122% less volatile than the broader market.

Connect Biopharma has a net margin of 0.00% compared to CytomX Therapeutics' net margin of -166.40%. CytomX Therapeutics' return on equity of -36.61% beat Connect Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CytomX Therapeutics	-166.40%	-36.61%	-28.02%
Connect Biopharma	N/A	-122.29%	-97.07%

Summary

CytomX Therapeutics beats Connect Biopharma on 10 of the 17 factors compared between the two stocks.

How does Connect Biopharma compare to Neurogene?

Neurogene (NASDAQ:NGNE) and Connect Biopharma (NASDAQ:CNTB) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, institutional ownership, profitability, media sentiment, dividends and earnings.

In the previous week, Connect Biopharma had 1 more articles in the media than Neurogene. MarketBeat recorded 4 mentions for Connect Biopharma and 3 mentions for Neurogene. Connect Biopharma's average media sentiment score of 0.89 beat Neurogene's score of 0.63 indicating that Connect Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neurogene	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Connect Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Neurogene currently has a consensus target price of $84.83, indicating a potential upside of 164.86%. Connect Biopharma has a consensus target price of $7.17, indicating a potential upside of 225.02%. Given Connect Biopharma's higher probable upside, analysts clearly believe Connect Biopharma is more favorable than Neurogene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neurogene	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	3.00
Connect Biopharma	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	3.00

Connect Biopharma has lower revenue, but higher earnings than Neurogene. Neurogene is trading at a lower price-to-earnings ratio than Connect Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neurogene	$930K	544.17	-$90.35M	-$4.55	N/A
Connect Biopharma	$60K	2,313.78	-$55.48M	-$1.15	N/A

Neurogene's return on equity of -37.88% beat Connect Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neurogene	N/A	-37.88%	-34.70%
Connect Biopharma	N/A	-122.29%	-97.07%

Neurogene has a beta of 1.69, meaning that its stock price is 69% more volatile than the broader market. Comparatively, Connect Biopharma has a beta of -0.22, meaning that its stock price is 122% less volatile than the broader market.

52.4% of Neurogene shares are owned by institutional investors. Comparatively, 58.7% of Connect Biopharma shares are owned by institutional investors. 11.7% of Neurogene shares are owned by insiders. Comparatively, 22.6% of Connect Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Connect Biopharma beats Neurogene on 10 of the 14 factors compared between the two stocks.

How does Connect Biopharma compare to Arvinas?

Arvinas (NASDAQ:ARVN) and Connect Biopharma (NASDAQ:CNTB) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, dividends, media sentiment, risk, valuation, profitability, analyst recommendations and institutional ownership.

Arvinas has a beta of 1.74, indicating that its share price is 74% more volatile than the broader market. Comparatively, Connect Biopharma has a beta of -0.22, indicating that its share price is 122% less volatile than the broader market.

Arvinas presently has a consensus price target of $15.42, suggesting a potential upside of 91.87%. Connect Biopharma has a consensus price target of $7.17, suggesting a potential upside of 225.02%. Given Connect Biopharma's stronger consensus rating and higher possible upside, analysts clearly believe Connect Biopharma is more favorable than Arvinas.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arvinas	2 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.46
Connect Biopharma	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Arvinas and Arvinas both had 4 articles in the media. Connect Biopharma's average media sentiment score of 0.89 beat Arvinas' score of 0.70 indicating that Connect Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arvinas	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Connect Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Connect Biopharma has lower revenue, but higher earnings than Arvinas. Arvinas is trading at a lower price-to-earnings ratio than Connect Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arvinas	$262.60M	1.97	-$80.80M	-$3.32	N/A
Connect Biopharma	$60K	2,313.78	-$55.48M	-$1.15	N/A

Connect Biopharma has a net margin of 0.00% compared to Arvinas' net margin of -247.54%. Arvinas' return on equity of -44.38% beat Connect Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arvinas	-247.54%	-44.38%	-28.38%
Connect Biopharma	N/A	-122.29%	-97.07%

95.2% of Arvinas shares are owned by institutional investors. Comparatively, 58.7% of Connect Biopharma shares are owned by institutional investors. 7.3% of Arvinas shares are owned by insiders. Comparatively, 22.6% of Connect Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Connect Biopharma beats Arvinas on 10 of the 16 factors compared between the two stocks.

How does Connect Biopharma compare to Sutro Biopharma?

Sutro Biopharma (NASDAQ:STRO) and Connect Biopharma (NASDAQ:CNTB) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, institutional ownership, valuation, profitability, media sentiment, analyst recommendations, earnings and dividends.

Connect Biopharma has a net margin of 0.00% compared to Sutro Biopharma's net margin of -154.21%. Sutro Biopharma's return on equity of 0.00% beat Connect Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sutro Biopharma	-154.21%	N/A	-69.20%
Connect Biopharma	N/A	-122.29%	-97.07%

In the previous week, Connect Biopharma had 2 more articles in the media than Sutro Biopharma. MarketBeat recorded 4 mentions for Connect Biopharma and 2 mentions for Sutro Biopharma. Sutro Biopharma's average media sentiment score of 0.93 beat Connect Biopharma's score of 0.89 indicating that Sutro Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sutro Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Connect Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

97.0% of Sutro Biopharma shares are owned by institutional investors. Comparatively, 58.7% of Connect Biopharma shares are owned by institutional investors. 3.6% of Sutro Biopharma shares are owned by insiders. Comparatively, 22.6% of Connect Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Connect Biopharma has lower revenue, but higher earnings than Sutro Biopharma. Sutro Biopharma is trading at a lower price-to-earnings ratio than Connect Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sutro Biopharma	$102.48M	4.93	-$191.09M	-$11.04	N/A
Connect Biopharma	$60K	2,313.78	-$55.48M	-$1.15	N/A

Sutro Biopharma presently has a consensus price target of $52.44, suggesting a potential upside of 71.84%. Connect Biopharma has a consensus price target of $7.17, suggesting a potential upside of 225.02%. Given Connect Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe Connect Biopharma is more favorable than Sutro Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sutro Biopharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.92
Connect Biopharma	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	3.00

Sutro Biopharma has a beta of 1.54, indicating that its stock price is 54% more volatile than the broader market. Comparatively, Connect Biopharma has a beta of -0.22, indicating that its stock price is 122% less volatile than the broader market.

Summary

Connect Biopharma beats Sutro Biopharma on 9 of the 16 factors compared between the two stocks.

How does Connect Biopharma compare to Kyverna Therapeutics?

Connect Biopharma (NASDAQ:CNTB) and Kyverna Therapeutics (NASDAQ:KYTX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, media sentiment, dividends, risk, institutional ownership and earnings.

Connect Biopharma has higher revenue and earnings than Kyverna Therapeutics. Kyverna Therapeutics is trading at a lower price-to-earnings ratio than Connect Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Connect Biopharma	$60K	2,313.78	-$55.48M	-$1.15	N/A
Kyverna Therapeutics	N/A	N/A	-$161.31M	-$3.28	N/A

Kyverna Therapeutics' return on equity of -81.88% beat Connect Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Connect Biopharma	N/A	-122.29%	-97.07%
Kyverna Therapeutics	N/A	-81.88%	-64.87%

58.7% of Connect Biopharma shares are held by institutional investors. Comparatively, 18.1% of Kyverna Therapeutics shares are held by institutional investors. 22.6% of Connect Biopharma shares are held by insiders. Comparatively, 17.6% of Kyverna Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Connect Biopharma has a beta of -0.22, meaning that its stock price is 122% less volatile than the broader market. Comparatively, Kyverna Therapeutics has a beta of 1.95, meaning that its stock price is 95% more volatile than the broader market.

In the previous week, Connect Biopharma had 1 more articles in the media than Kyverna Therapeutics. MarketBeat recorded 4 mentions for Connect Biopharma and 3 mentions for Kyverna Therapeutics. Connect Biopharma's average media sentiment score of 0.89 beat Kyverna Therapeutics' score of 0.63 indicating that Connect Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Connect Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Kyverna Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Connect Biopharma presently has a consensus price target of $7.17, indicating a potential upside of 225.02%. Kyverna Therapeutics has a consensus price target of $30.00, indicating a potential upside of 255.45%. Given Kyverna Therapeutics' higher probable upside, analysts clearly believe Kyverna Therapeutics is more favorable than Connect Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Connect Biopharma	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	3.00
Kyverna Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Connect Biopharma beats Kyverna Therapeutics on 10 of the 14 factors compared between the two stocks.

Get Connect Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CNTB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CNTB vs. The Competition

Export

Metric	Connect Biopharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$137.89M	$3.63B	$7.04B	$12.19B
Dividend Yield	N/A	2.21%	2.66%	6.24%
P/E Ratio	-1.92	21.56	26.13	24.17
Price / Sales	2,313.78	334.27	600.51	118.90
Price / Cash	N/A	141.14	47.95	55.62
Price / Book	2.94	8.33	10.78	6.36
Net Income	-$55.48M	$23.91M	$3.58B	$337.99M
7 Day Performance	10.25%	3.42%	2.22%	0.10%
1 Month Performance	-7.35%	0.39%	-0.09%	-1.28%
1 Year Performance	120.50%	65.22%	34.39%	27.68%

Connect Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CNTB Connect Biopharma	4.5141 of 5 stars	$2.21 +6.5%	$7.17 +225.0%	+120.5%	$137.89M	$60K	N/A	110	News Coverage Analyst Forecast Gap Up High Trading Volume
CTMX CytomX Therapeutics	2.8327 of 5 stars	$3.04 +3.1%	$12.10 +298.0%	+50.4%	$502.05M	$76.20M	N/A	170	Positive News
NGNE Neurogene	2.7561 of 5 stars	$32.25 +2.3%	$84.83 +163.0%	+98.2%	$498.23M	$930K	N/A	90	News Coverage
ARVN Arvinas	2.9353 of 5 stars	$7.74 +0.9%	$15.42 +99.2%	+6.6%	$494.88M	$262.60M	N/A	420	Analyst Downgrade
STRO Sutro Biopharma	3.1403 of 5 stars	$31.55 +6.5%	$52.44 +66.2%	+315.8%	$490.98M	$102.48M	N/A	240	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CNTB) was last updated on 6/28/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Connect Biopharma (CNTB) Competitors

CNTB vs. CTMX, NGNE, ARVN, STRO, and KYTX

How does Connect Biopharma compare to CytomX Therapeutics?

Summary

How does Connect Biopharma compare to Neurogene?

Summary

How does Connect Biopharma compare to Arvinas?

Summary

How does Connect Biopharma compare to Sutro Biopharma?

Summary

How does Connect Biopharma compare to Kyverna Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNTB vs. The Competition

Connect Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Connect Biopharma (CNTB) Competitors

CNTB vs. CTMX, NGNE, ARVN, STRO, and KYTX

How does Connect Biopharma compare to CytomX Therapeutics?

Do insiders and institutionals believe in CTMX or CNTB?

Which has better valuation & earnings, CTMX or CNTB?

Do analysts recommend CTMX or CNTB?

Does the media favor CTMX or CNTB?

Which has more risk & volatility, CTMX or CNTB?

Is CTMX or CNTB more profitable?

Summary

How does Connect Biopharma compare to Neurogene?

Does the media refer more to NGNE or CNTB?

Do analysts prefer NGNE or CNTB?

Which has stronger earnings & valuation, NGNE or CNTB?

Is NGNE or CNTB more profitable?

Which has more risk & volatility, NGNE or CNTB?

Do insiders and institutionals believe in NGNE or CNTB?

Summary

How does Connect Biopharma compare to Arvinas?

Which has more risk & volatility, ARVN or CNTB?

Do analysts rate ARVN or CNTB?

Does the media favor ARVN or CNTB?

Which has higher earnings & valuation, ARVN or CNTB?

Is ARVN or CNTB more profitable?

Do insiders & institutionals hold more shares of ARVN or CNTB?

Summary

How does Connect Biopharma compare to Sutro Biopharma?

Is STRO or CNTB more profitable?

Does the media prefer STRO or CNTB?

Do insiders and institutionals have more ownership in STRO or CNTB?

Which has higher earnings & valuation, STRO or CNTB?

Do analysts rate STRO or CNTB?

Which has more volatility and risk, STRO or CNTB?

Summary

How does Connect Biopharma compare to Kyverna Therapeutics?

Which has better earnings & valuation, CNTB or KYTX?

Is CNTB or KYTX more profitable?

Do institutionals & insiders believe in CNTB or KYTX?

Which has more volatility & risk, CNTB or KYTX?

Does the media refer more to CNTB or KYTX?

Do analysts rate CNTB or KYTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNTB vs. The Competition

Connect Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools